Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial.
Biannual rituximab infusions over 18 months effectively maintain remission after a "standard" remission induction regimen for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). ⋯ French Ministry of Health and Hoffmann-La Roche.